ONGLYZA Drug Patent Profile

Which patents cover Onglyza, and what generic alternatives are available?

Onglyza is a drug marketed by Astrazeneca Ab and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty-seven patent family members in thirty-two countries.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the saxagliptin hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Onglyza

Onglyza was eligible for patent challenges on July 31, 2013.

There have been fifteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (saxagliptin hydrochloride), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for ONGLYZA

International Patents:	57
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	51
Clinical Trials:	69
Patent Applications:	6,916
Drug Prices:	Drug price information for ONGLYZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ONGLYZA
What excipients (inactive ingredients) are in ONGLYZA?	ONGLYZA excipients list
DailyMed Link:	ONGLYZA at DailyMed

See drug prices for ONGLYZA

See drug sales revenues for ONGLYZA

Recent Clinical Trials for ONGLYZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
UnitedHealthcare	PHASE2
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	PHASE2
Ain Shams University	N/A

See all ONGLYZA clinical trials

Paragraph IV (Patent) Challenges for ONGLYZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ONGLYZA	Tablets	saxagliptin hydrochloride	2.5 mg and 5 mg	022350	8	2013-07-31

US Patents and Regulatory Information for ONGLYZA

ONGLYZA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	ONGLYZA	saxagliptin hydrochloride	TABLET;ORAL	022350-001	Jul 31, 2009		DISCN	Yes	No	7,951,400		Y
Astrazeneca Ab	ONGLYZA	saxagliptin hydrochloride	TABLET;ORAL	022350-002	Jul 31, 2009		DISCN	Yes	No	7,951,400		Y

Expired US Patents for ONGLYZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	ONGLYZA	saxagliptin hydrochloride	TABLET;ORAL	022350-001	Jul 31, 2009	6,395,767
Astrazeneca Ab	ONGLYZA	saxagliptin hydrochloride	TABLET;ORAL	022350-002	Jul 31, 2009	6,395,767
Astrazeneca Ab	ONGLYZA	saxagliptin hydrochloride	TABLET;ORAL	022350-001	Jul 31, 2009	RE44186
Astrazeneca Ab	ONGLYZA	saxagliptin hydrochloride	TABLET;ORAL	022350-002	Jul 31, 2009	RE44186

International Patents for ONGLYZA

See the table below for patents covering ONGLYZA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	027634	INHIBIDORES A BASE DE PIRROLIDINA FUSIONADA CON CICLOPROPILO DE DIPEPTIDIL PEPTIDASA IV, METODO DE TRATAMIENTO Y COMPOSICION FARMACEUTICA.
Austria	396176
Australia	2001245466
Australia	4546601
Belgium	2010C008

Supplementary Protection Certificates for ONGLYZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1084705	C300707	Netherlands		PRODUCT NAME: SAXAGLIPTIN; REGISTRATION NO/DATE: EU/1/09/545/001-010 20091001
1084705	CA 2014 00062	Denmark		PRODUCT NAME: SAXAGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER SAXAGLIPTIN HYDROCHLORID; REG. NO/DATE: EU/1/09/545/001-015 20091001
1084705	PA2014043	Lithuania		PRODUCT NAME: SAXAGLIPTINUM; REGISTRATION NO/DATE: EU/1/09/545/001-015 20091001
1084705	C01084705/03	Switzerland		PRODUCT NAME: SAXAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 59390 05.02.2010
1261586	C300436	Netherlands		PRODUCT NAME: SAXAGLIPTINE, ALSMEDE; REGISTRATION NO/DATE: EU/1/09/545/001-010 20091001

ONGLYZA (saxagliptin) market dynamics and financial trajectory: sales trends, share drivers, payer constraints, and exclusivity-to-generic risk

Last updated: July 22, 2026

Executive summary: ONGLYZA (saxagliptin) faces structurally limited upside from competitive GLP-1 and SGLT2 demand and entrenched formulary positioning of lower-cost DPP-4 options. Financial trajectory is dominated by (1) DPP-4 class pricing pressure after generic entry, (2) incremental prescribing shifts toward newer cardiometabolic agents, and (3) manufacturer-specific liquidity from litigation and contract renewals rather than new clinical launches. For business planning, the core risk is continued margin compression from supply normalization and competitive channel reallocations rather than remaining on-patent growth.

---

What is ONGLYZA (saxagliptin) and how is it sold in the U.S. market?

Quick answer: ONGLYZA is a DPP-4 inhibitor used for type 2 diabetes, marketed in the U.S. primarily as 5 mg and 2.5 mg tablets (once daily). Commercial performance is tied to managed-care formularies, patient adherence, and substitution dynamics across DPP-4, GLP-1 receptor agonists, and SGLT2 inhibitors.

Core commercial positioning

ONGLYZA’s market role is generally “low-complexity oral add-on” for patients needing additional glycemic control without injectable escalation. That positioning keeps it relevant in segments where:

• Injections face payer restrictions or patient refusal.
• Cost-sensitive formularies cap non-preferred therapies.
• Prior DPP-4 users remain stable if coverage remains unchanged.

Where ONGLYZA competes most directly

• Other DPP-4 inhibitors: sitagliptin (Januvia and generics), linagliptin (Tradjenta and generics), alogliptin (Nesina and generics), and combination products.
• Newer cardiometabolic classes: GLP-1 receptor agonists and SGLT2 inhibitors, which have expanded due to weight, renal, and cardiovascular outcomes benefits.

---

When did ONGLYZA face exclusivity loss and generic entry risk in the U.S.?

Quick answer: The market’s financial inflection for ONGLYZA is largely tied to DPP-4 generics’ penetration across formularies rather than a single patent date. In practice, DPP-4 class pricing resets after major generic availability and PBM contracting changes.

Exclusivity dynamics that matter commercially

For a small-molecule tablet like ONGLYZA, the commercial outcome is driven by:

• Time-to-generic substitution at the pharmacy counter.
• PBM rebate restructuring and “preferred” class swaps.
• Contracting that prices generics as class anchors and moves branded volume to restricted segments.

Patent versus practical market erosion

Even where branded “evergreening” exists, the financial trajectory typically tracks:

• Switch from branded to generic DPP-4 prescribing in claims data.
• Reduced copays and step edits favoring generic entries.
• Margin compression for brand via rebate declines.

---

What is the ONGLYZA sales and revenue trajectory over time?

Quick answer: ONGLYZA’s revenue trajectory has generally followed a mature branded pattern: mid-life growth or stabilization followed by plateau and then declining net sales as generic DPP-4 options became dominant in managed care.

How DPP-4 revenue typically evolves post-competition

For oral DPP-4 inhibitors, net sales often move in phases:

1. Brand growth and formulary establishment (higher price realization).
2. Increased PBM pressure and rebate escalation (brand margin compression).
3. Generic substitution and class-level price resets (brand unit decline).
4. Remaining brand in niche accounts or where coverage uses tiering rather than full switch.

Financial drivers for branded DPP-4 performance

• Net price: rebound or collapse based on contracting.
• Volume: affected by market share versus DPP-4 peers and cross-class shifts toward GLP-1 and SGLT2.
• Patient mix: older, comorbidity-heavy cohorts can remain stable on DPP-4, but outcomes-driven payer mandates can shift add-ons.

---

How did payer and formulary decisions change ONGLYZA demand?

Quick answer: Demand is primarily shaped by PBM preference design. When generics become preferred, branded saxagliptin volume shifts to lower-cost DPP-4 alternatives or to other agent classes on outcomes-based formularies.

Typical formulary mechanics affecting ONGLYZA

• DPP-4 tier changes: moving branded from preferred to non-preferred.
• Step edits: requiring failure on cheaper agents (generic DPP-4, then SGLT2/GLP-1).
• Quantity limits and prior authorization for higher-cost therapies that begin to displace DPP-4 in high-risk subgroups.

Net effect on business metrics

• Lower branded volume and higher rebate burden.
• Reduced average selling price if payer contracts move quickly to benchmark generic pricing.

---

What clinical-safety and labeling scrutiny risks affected ONGLYZA utilization?

Quick answer: ONGLYZA has faced heightened scrutiny linked to cardiovascular safety discussions within the DPP-4 class and specific messaging in product labeling. That kind of scrutiny can affect prescribing behavior even without immediate wholesale discontinuation.

How labeling impacts market dynamics

Prescribers calibrate:

• Baseline risk in patients with established cardiovascular disease or risk factors.
• Choice between saxagliptin versus other DPP-4 members with different outcome profiles and patient fit perceptions.

Commercial implication

Net sales trajectories can slow even before generics enter because:

• Providers shift to preferred alternatives within the class.
• Payers may impose tighter restrictions on branded saxagliptin if safer or cheaper class members are available.

---

Which companies own ONGLYZA and who manufactures it after brand and generic shifts?

Quick answer: ONGLYZA’s brand origin sits with AstraZeneca in the U.S. market historically, with eventual generic participation by multiple manufacturers as approvals and market entry proceed.

Competitive supply landscape

Once generics land, the market typically transitions to:

• Multiple ANDA suppliers distributing through standard wholesaler channels.
• PBMs favoring specific products based on contract pricing and rebates.

Why this matters financially

Multiple generic suppliers increase:

• Price competition.
• Margin compression.
• Risk that brand-to-generic switching accelerates after contract milestones.

---

How many competing DPP-4 inhibitors does ONGLYZA face, and how do their market positions compare?

Quick answer: ONGLYZA competes with the full DPP-4 lineup, with sitagliptin-based products generally having the largest installed base historically. After generic availability, class switching becomes a pricing and formulary matter rather than differentiation-led prescribing.

DPP-4 competitive matrix (U.S.-focused)

Active ingredient	Brand(s) (historical)	Competitive role vs saxagliptin	Key commercial dynamic
Sitagliptin	Januvia	Often largest installed base	Generic pricing and formulary anchors
Linagliptin	Tradjenta	Strong niche in CKD perception	Class switching under PBM contracts
Alogliptin	Nesina	Regional/formulary dependent	Competitive pricing after generics
Saxagliptin	ONGLYZA	Branded share constrained over time	Prescriber and payer preference shifts

---

What drives switching from ONGLYZA to GLP-1 and SGLT2 therapies?

Quick answer: The switching driver is outcomes-based payer design and evolving clinical practice favoring GLP-1 receptor agonists and SGLT2 inhibitors in high-risk type 2 diabetes populations.

High-intent payer controls

• Preferential placement of agents with kidney and cardiovascular risk evidence.
• Reduced coverage for DPP-4 in patients meeting criteria for SGLT2/GLP-1 initiation.

Practical impact on ONGLYZA

Even with DPP-4 generics available, the main branded revenue compression risk comes from:

• Lost opportunity to expand share in earlier line therapy.
• Patient capture shifting toward newer agents in commercial and Medicare Advantage plans.

---

What is the Orange Book status of ONGLYZA, and how does it affect generic entry timing?

Quick answer: The Orange Book framework governs ANDA approval and patent-triggered litigation, but the commercial outcome is usually determined by when generics are stocked and preferred on formularies.

How Orange Book listings translate into real market outcomes

For tablets like ONGLYZA, the effective market timeline can be shorter than patent life because:

• Courts/settlements can accelerate generic launch.
• PBM contracting dictates uptake post-launch.
• Multiple generic approvals create fast erosion.

---

What patent litigation or Paragraph IV challenges affected ONGLYZA generics and timelines?

Quick answer: ONGLYZA’s patent landscape has supported generic litigation typical for established brands. The financial impact is in settlement terms, timing of launch, and design-around risk for follow-on formulations.

Litigation-to-commercial mapping

Key financial outcomes of patent challenges include:

• Launch date carveouts.
• Marketing exclusivity triggers tied to exclusivity awards.
• Scope limitations on generic product parameters.

---

What formulations or method-of-use patents exist for ONGLYZA, and do they matter commercially?

Quick answer: For DPP-4 brands, the commercially relevant patent set usually includes composition claims, use claims tied to dosing populations, and potentially formulation-specific patents. Method-of-use protection is less likely to block generic tablet entry unless specific labeling claims are restricted.

Typical patent categories that influence business strategy

• Composition of matter: can block generics longer if still in force.
• Use/dosing: can influence label content and substitution.
• Formulation/manufacturing: usually targeted in ANDA quality or design-around, but impacts are often secondary to substitution speed.

---

How strong is the ONGLYZA patent estate, and is it defensible in litigation?

Quick answer: ONGLYZA is a mature small-molecule. Defensibility is assessed less on abstract claim strength and more on whether remaining claims can survive ANDA litigation and sustain label barriers at launch.

Practical defensibility factors

• Claim construction risk under district court precedent.
• Prior art density typical in mature diabetes small molecules.
• Ability for generic applicants to carve out or design around.

---

What are the generic launch scenarios for ONGLYZA, and what entry risks exist?

Quick answer: The generic market structure for ONGLYZA typically evolves through multiple successive ANDA entrants, with the highest entry risk tied to litigation timing and settlement constraints.

Generic entry playbook outcomes

• Scenario A: “early launch after settlement” creates rapid unit substitution and heavy price competition.
• Scenario B: “staggered launch” delays full market erosion and sustains branded residual share longer.
• Scenario C: “design-around success” accelerates generic availability even when some patent claims remain contested.

---

What is the likely financial exposure from ONGLYZA’s market erosion for brand stakeholders?

Quick answer: Financial exposure is driven by:

• Residual branded unit share decline.
• Gross-to-net margin compression from rebate renegotiations.
• Increased volatility from wholesaler inventory cycles and contract resets.
• Loss of incremental prescriptions as clinicians prioritize GLP-1/SGLT2 in earlier lines.

---

Key Takeaways

• ONGLYZA operates as a mature, formulary-sensitive oral DPP-4. Its financial trajectory is dominated by generic substitution, PBM preference shifts, and cross-class migration to GLP-1 and SGLT2 therapies.
• The highest leverage for ONGLYZA is contracting and channel preference, not new product differentiation.
• Litigation and patent estates matter mainly to the calendar of launch and label barriers; the enduring commercial effect comes from how quickly generics become preferred and stocked.
• The principal risk to remaining branded economics is continued DPP-4 price pressure plus narrowing growth windows as outcomes-based formularies favor newer agents.

---

FAQs

1) Does ONGLYZA still grow in the U.S. market after DPP-4 generic penetration?
Growth, if any, is typically limited to residual share in accounts that retain branded tiers or in prescriber-specific routines; class-wide volume trends are usually negative as PBMs anchor to the lowest-cost preferred options.

2) How does ONGLYZA compare with sitagliptin (Januvia) on competitive and pricing dynamics?
Sitagliptin generally benefits from broader installed base and payer familiarity, while ONGLYZA’s economics are more exposed to narrower formulary niches and subsequent pricing benchmarking after generic uptake.

3) What lines of therapy most influence ONGLYZA prescribing?
ONGLYZA’s demand is most tied to add-on or second-line coverage rules, where outcomes-based payer criteria increasingly route high-risk patients to GLP-1 or SGLT2 options.

4) How do Medicare Advantage formularies typically affect DPP-4 brand survival?
They commonly enforce tiering and step edits that steer patients to preferred lower-cost agents, accelerating branded erosion for mature DPP-4 products once generic options are available.

5) What commercialization lesson does ONGLYZA offer for future diabetes small molecules?
The long-term driver is not clinical nuance alone; it is payer mechanics that reallocate market share toward therapies with outcomes evidence plus competitive pricing once generics enter.

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. U.S. Food and Drug Administration. (n.d.). Drug Approval Reports and related documents for saxagliptin/ONGLYZA. FDA.

DrugChatter Q&A for ONGLYZA

What's the timeline for onglyza's generic version?
Onglyza generic availability?
Onglyza us patent expiration date?
Onglyza patent expiration date?
Who is the patent owner of onglyza?